CP
ATOS icon

Castleview Partners’s Atossa Therapeutics ATOS Stock Holding History

Castleview Partners’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-33
Closed -$440 – 906
2023
Q4 		$440 Hold
33
– – ﹤0.01% 808
2023
Q3 		$368 Hold
33
– – ﹤0.01% 648
2023
Q2 		$630 Hold
33
– – ﹤0.01% 657
2023
Q1 		$362 Hold
33
– – ﹤0.01% 647
2022
Q4 		$264 Hold
33
– – ﹤0.01% 606
2022
Q3 		$0 Buy
33
+27
+450% +$392 ﹤0.01% 618
2022
Q2 		$110 Sell
6
-27
-82% -$425 ﹤0.01% 748
2022
Q1 		$0 Buy
+33
New +$670 ﹤0.01% 701
2021
Q2 		$3K Buy
+33
New +$1.75K ﹤0.01% 822

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Castleview Partners's ATOS Position: Q1 2024 in Review

Castleview Partners sold out of Atossa Therapeutics (ATOS) in Q1 2024, closing a stake of 33 shares — an estimated $440 sold.

Castleview Partners first reported a position in ATOS in Q2 2021 and held it in 9 quarters. The position peaked at $3K in Q2 2021. 67 funds tracked by Wall St. Rank hold ATOS as of Q1 2024.

  • Castleview Partners reported no remaining Atossa Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Castleview Partners sold 33 Atossa Therapeutics shares in Q1 2024, an estimated $440.
  • Castleview Partners first reported a position in Atossa Therapeutics in Q2 2021 and held it in 9 quarters.
  • Castleview Partners's Atossa Therapeutics position peaked at $3K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2024.

Based on Castleview Partners's 13F filing for Q1 2024, filed 10 May 2024.